NCTN Brain Cancer Trials Portfolio (Open as of 5/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:



NCTN Brain Cancer Trials (Open as of 5/15/2025)

Protocol Number	Phase	Protocol Title
		Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2
A071401	П	Mutations
A071701	11	Genomically-Guided Treatment Trial in Brain Metastases
		A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically
A071702	П	Hypermutated Recurrent Glioblastoma
		Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent
A072201	П	Glioblastoma
		A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT)
CCTG CE.7	ш	for 5-15 Brain Metastases
EAF223	П	Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)
NRG-BN003	Ш	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
		A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard
NRG-BN011	ш	Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
		A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic
NRG-BN012	Ш	Radiosurgery in Patients with Resectable Brain Metastases
		Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for
NRG-BN013	Ш	Intact Brain Metastases
		A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field
		Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal
NRG-BN014	Ш	Metastasis (Radiate-LM)
EAY191		Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	П	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced
EAY191-E5	П	Solid Tumors: A ComboMATCH Treatment Trial
		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib,
		a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A
EAY191-N5	II	ComboMATCH Treatment Trial
		Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory
		Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment
EAY191-S3	П	Trial